Holen Sie sich die Stockscreener-App
8.82
3.29%
-0.30
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
News impact scoring models applied to REGENXBIO Inc.Rate Hike & Low Drawdown Investment Strategies - Newser
Candlestick signals on REGENXBIO Inc. stock todayJuly 2025 Decliners & Reliable Volume Spike Trade Alerts - Newser
Trend analysis for REGENXBIO Inc. this weekJuly 2025 Decliners & High Conviction Buy Zone Picks - Newser
Applying Wyckoff theory to REGENXBIO Inc. stock2025 Top Gainers & Free Technical Pattern Based Buy Signals - Newser
Is this a good reentry point in REGENXBIO Inc.2025 Technical Patterns & High Yield Stock Recommendations - Newser
Has REGENXBIO Inc. found a price floor2025 Volatility Report & Free Weekly Watchlist of Top Performers - Newser
What recovery options are there for REGENXBIO Inc.Earnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Will REGENXBIO Inc. price bounce be sustainableTrade Risk Summary & Safe Entry Zone Identification - Newser
How moving averages guide REGENXBIO Inc. trading2025 Risk Factors & Safe Swing Trade Setup Alerts - Newser
REGENXBIO Inc. recovery potential after sell offWeekly Risk Summary & Free Real-Time Market Sentiment Alerts - Newser
What MACD signals say about REGENXBIO Inc.Breakout Watch & Weekly Chart Analysis and Guides - Newser
REGENXBIO Inc. Volume Confirms Breakout — Analysts Bullish getLinesFromResByArray error: size == 0 - 더경남뉴스
Detecting price anomalies in REGENXBIO Inc. with AINew Guidance & Verified Swing Trading Watchlist - Newser
Can trapped investors hope for a rebound in REGENXBIO Inc.Portfolio Return Summary & Expert Approved Trade Ideas - Newser
Can REGENXBIO Inc. recover in the next quarterShare Buyback & Real-Time Buy Signal Notifications - Newser
Detecting support and resistance levels for REGENXBIO Inc.July 2025 Macro Moves & High Return Trade Opportunity Guides - Newser
FDA Bumps Back PDUFA for REGENXBIO's MPS II Gene Therapy RGX-121 - CGTLive®
Technical analysis overview for REGENXBIO Inc. stock2025 Trading Recap & Risk Controlled Stock Alerts - Newser
Published on: 2025-08-25 00:19:26 - Newser
Is a relief rally coming for REGENXBIO Inc. holders2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
When is the best time to exit REGENXBIO Inc.July 2025 Setups & Fast Entry Momentum Trade Alerts - Newser
What candlestick patterns are forming on REGENXBIO Inc.Exit Point & Daily Technical Forecast Reports - Newser
What’s the beta of REGENXBIO Inc. stockJuly 2025 Levels & Daily Chart Pattern Signals - theviewers.co.kr
Can REGENXBIO Inc. expand its profit marginsExit Point & Growth Focused Investment Plans - 더경남뉴스
Drawdown in REGENXBIO Inc. May Be Nearing End2025 Volume Leaders & Free Fast Gain Swing Trade Alerts - beatles.ru
Is There Enough Volume to Lift REGENXBIO Inc.2025 Major Catalysts & Short-Term Trading Opportunity Alerts - 더경남뉴스
Should value investors consider REGENXBIO Inc.Weekly Trend Report & Low Volatility Stock Suggestions - theviewers.co.kr
Regenxbio FDA delay ‘not a needle mover,’ says Leerink - MSN
DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay - insights.citeline.com
Regenxbio RGNX: HC Wainwright & Co. Maintains Buy Rating with $34 Price Target - AInvest
Regenxbio's FDA Review Delay Won't Impact Shares Significantly: Leerink Analyst - AInvest
Delay hits Regenxbio BLA review - The Pharma Letter
What momentum shifts mean for REGENXBIO Inc.2025 Biggest Moves & Short-Term Trading Alerts - Newser
What’s next for REGENXBIO Inc. stock priceQuarterly Profit Report & Stepwise Entry/Exit Trade Alerts - Newser
Regenxbio says FDA extends review date for Hunter syndrome drug - MSN
Volume spikes in REGENXBIO Inc. stock – what they meanQuarterly Market Review & Daily Price Action Insights - Newser
FDA Extends Review Period for REGENXBIO Hunter Syndrome Treatment - BioPharm International
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Benzinga
FDA delays decision on Regenxbio gene therapy - statnews.com
Regenxbio stock steady as FDA extends RGX-121 review timeline - Investing.com
Regenxbio Inc. shares rise 1.49% premarket after FDA review extension for RGX-121. - AInvest
Regenxbio stock holds steady as FDA extends review of Hunter syndrome gene therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy By Investing.com - Investing.com Nigeria
Regenxbio Says FDA Extends Review Timeline for RGX-121 - MarketScreener
Regenxbio's FDA Review Extension for RGX-121 and Its Implications for Gene Therapy Commercialization - AInvest
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):